MXCT News and Press, MaxCyte Inc. From 10/05/23

2023-10-05 08:16:47 ET More on BioXcel Therapeutics, Lithium Americas Corp., etc. Lithium Americas (Argentina): An Outrageously Undervalued Lithium Company BioXcel: Navigating The Peaks And Valleys Of Regulatory Uncertainties BioXcel's Struggles: From FDA Issues To F...

2023-10-05 05:48:00 ET NASDAQ: RIVN plunged more than 9% Related stories BlackBerry Limited (BB) Q2 2024 Earnings Call Transcript Does Rivian Still Have An Existential Crisis? BlackBerry Earnings Preview: Pre-Announcement May Not Save Further Sell-Off ...

2023-10-04 16:49:14 ET More on MaxCyte MaxCyte: Still Bullish Despite Soft Q2 Earnings MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript MaxCyte gains on licensing pact for cell therapies Seeking Alpha’s Quant Rating on MaxCyte Historical e...

ROCKVILLE, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioproce...

ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to supp...

ROCKVILLE, Md., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, developme...

2023-08-21 17:18:40 ET Summary MaxCyte reported a 5.9% decrease in Q2 revenue, attributing it to funding environments and the prioritization of internal pipeline assets. The company remains optimistic about their Strategic Platform License revenue and has signed five partnerships ...

2023-08-09 22:13:09 ET MaxCyte, Inc. (MXCT) Q2 2023 Earnings Conference Call August 09, 2023, 04:30 PM ET Company Participants Sean Menarguez - Head-IR Doug Doerfler - President and CEO Douglas Swirsky - CFO Conference Call Participants Julie Simmonds...

2023-08-09 16:57:09 ET MaxCyte press release ( NASDAQ: MXCT ): Q2 GAAP EPS of -$0.10 in-line. Revenue of $9.04M (-5.9% Y/Y) misses by $1.62M . Shares -4.59% . For further details see: MaxCyte GAAP EPS of -$0.10 in-line, revenue of $9.04M misses by $1.62M

ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, developmen...